Payment overview · 2025
General Payments
$1,347.29
46 reported records · 12 companies
Healthcare provider profile · identity verified
Everett W. Campbell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DETROIT, MI · NPI 1710046792
Verified facts
What the public records show
CMS Open Payments records show Everett W. Campbell, M.D. received $1,347.29 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $416.68 | 30.9% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $190.85 | 14.2% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $147.47 | 10.9% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 9.3% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $113.25 | 8.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $102.50 | 7.6% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.13 | 5.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.18 | 5.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.42 | 3.6% | 3 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $21.43 | 1.6% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $19.33 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.05 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,347.29 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $181.45 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $147.47 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $140.36 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $116.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $102.50 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.13 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $75.40 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $74.75 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.14 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.42 | 3 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 30 |
| Omeprazole | Omeprazole | 174 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 171 | 32 |
| Gabapentin | Gabapentin | 154 | 41 |
| Metformin Hcl | Metformin Hcl | 152 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 144 | 23 |
| Losartan Potassium | Losartan Potassium | 136 | 25 |
| Ibuprofen | Ibuprofen | 116 | 30 |
| Potassium Chloride | Potassium Chloride | 114 | 31 |
| Lisinopril | Lisinopril | 111 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 106 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 22 |
| Simvastatin | Simvastatin | 91 | 11 |
| Famotidine | Famotidine | 89 | 19 |
| Hydrocortisone | Hydrocortisone | 89 | 25 |
| Promethazine Hcl | Promethazine Hcl | 86 | 29 |
| Nifedipine Er | Nifedipine | 85 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 17 |
| Metformin Hcl Er | Metformin Hcl | 81 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 20 |
| Furosemide | Furosemide | 71 | 22 |
| Naproxen | Naproxen | 71 | 14 |
| Atenolol | Atenolol | 68 | suppressed |
| Carvedilol | Carvedilol | 68 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 13 |
| Acyclovir | Acyclovir | 60 | suppressed |
| Jardiance | Empagliflozin | 57 | 11 |
| Ozempic | Semaglutide | 57 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 11 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 50 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 49 | suppressed |
| Glipizide | Glipizide | 46 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Allopurinol | Allopurinol | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Alprazolam | Alprazolam | 39 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 11 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,347.29 · 46 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, FARXIGA, JARDIANCE, MOUNJARO, NEFFY, Saxenda, TRELEGY ELLIPTA, TWIIST, VERQUVO, VOQUEZNA, Wegovy, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error